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Accumulating evidence indicates that ATP-binding cassette (ABC) transporter ABCG2 plays a key role in regulating the cellular
accumulation of porphyrin derivatives in cancer cells and thereby aﬀects the eﬃcacy of photodynamic therapy and photodynamic
diagnosis. The activity of porphyrin eﬄux can be aﬀected by genetic polymorphisms in the ABCG2 gene. On the other hand, Nrf2,
an NF-E2-related transcription factor, has been shown to be involved in oxidative stress-mediated induction of the ABCG2 gene.
Since patients have demonstrated individual diﬀerences in their response to photodynamic therapy, transcriptional activation
and/or genetic polymorphisms of the ABCG2 gene in cancer cells may aﬀect patients’ responses to photodynamic therapy. Protein
kinase inhibitors, including imatinib mesylate and geﬁtinib, are suggested to potentially enhance the eﬃcacy of photodynamic
therapy by blocking ABCG2-mediated porphyrin eﬄux from cancer cells. This review article provides an overview on the role of
human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis.
1.Introduction
Photodynamic therapy (PDT) and photodynamic diagnosis
are achieved by a photon-induced physicochemical reaction
which is induced by excitation of photosensitizer exposed
to light. In the 1960s Lipson and Baldes introduced a
hematoporphyrin derivative (HpD), a product derived fol-
lowing by treatment of hematoporphyrin with a mixture of
acetic and sulfuric acids and sodium hydroxide [1]. Their
development of the hematoporphyrin derivative established
the basis of today’s PDT and photodynamic diagnosis [2–
6]. PDT utilizes porphyrin derivatives to generate singlet
oxygen (1O2) and other reactive oxygen species (ROS) that
are potent in killing cancer cell in vivo [7]. The modern
era of PDT was founded in the 1970s with the pioneering
work of Dougherty and his coworkers who puriﬁed HpD
later called Photofrin. In 1978, Dougherty et al. had carried
out the ﬁrst human trials of Photofrin on women with
advanced breast cancer [8]. Photofrin is still the most
widely used photosensitizer in clinical PDT. Recent studies
of modern PDT began just two decades ago; therefore there
are still unsolved problems. Nevertheless, PDT has many
applications in a wide range of ﬁelds of both preclinical and
clinical sciences.
In recent years, remarkable advances were made in
photodynamic diagnosis technology that makes it easier to
reliably achieve complete excision of malignant gliomas [9–
11] and meningiomas [12]. The extent of tumor resection
that should be undertaken in patients with glioblastoma
multiforme remained controversial [13, 14]. Fluorescence-
guided gross-total resection has been developed and it has
prolonged the survival time of glioblastoma and menin-
gioma patients [9–12, 15, 16]. Historically, two ﬂuorescent
agents, that is, ﬂuorescein sodium and protoporphyrin IX
(PpIX) induced by δ-Aminolevulinic acid (ALA) or its ester,
have been used in glioma surgery. Because of its high
tumor speciﬁcity and safety, ALA is particularly promising.
It actively accumulates in the neoplasm and is converted2 Advances in Pharmacological Sciences
to PpIX which is ﬂuorescent. This phenomenon has been
clinically applied to the detection of neoplasms in the brain
and other organs, such as the bladder, skin, and bronchus.
This technique is generally termed ﬂuorescence diagnosis or
photodynamicdiagnosis.Fluorescence-guidedresectionmay
be beneﬁcial for the removal of complicated or malignant
tumors that have a high risk of recurrence. The most
important point in ﬂuorescence-guided microsurgery is the
use of good equipment that can provide suﬃcient operative
ﬁelds even under ﬂuorescence mode.
2.Biosynthesis andMetabolismof
Porphyrins and Heme
Hemes play critical roles in diverse biological processes,
such as respiration and oxidative metabolism [17, 18].
Both heme biosynthesis and its intracellular concentration
are tightly regulated. Heme molecules are formed via an
eight-stepped pathway that is spatially shared between
mitochondria and cytoplasmic compartments (Figure 1).
At the ﬁrst step, ALA is synthesized from glycine and
succinyl Co-A in a reaction catalyzed by ALA-synthase and
regulated by the intracellular-free heme pool. After ALA
synthesis, a sequence of reactions occur leading to the
production of various porphyrin compounds. Finally, as a
result of ferrochelatase action, ferrous iron is incorporated
into PpIX to form heme. Heme production as well as
the synthesis of its two immediate precursors (PpIX and
protoporphyrinogen) occurs in the mitochondria. ABCB6,
one of human ABC transporters, reportedly transports
coproporphyrinogen III from the cytoplasm to the mito-
chondria [19], whereas another ABC transporter ABCG2
is responsible for the cellular homeostasis of porphyrins
and their related compounds [20]. Disturbances in cellu-
lar heme biosynthesis or metabolism are associated with
several types of porphyria, which represent an elevation of
toxic hemeprecursors, for example, protoporphyrins [21–
23].
3. Enforced Biosynthesis of Protoporphyrin
IX inCancer Cellsby ALA Administration
ExogenousALAadministrationshort-circuitstheﬁrststepof
porphyrin biosynthesis (Figure 1), where ALA is transported
into cancer and normal cells by oligopeptide transporter
1o r2( P E P T 1o rP E P T 2 ) .A L Ai n d u c e st h ea c c u m u l a t i o n
of detectable amounts of PpIX in certain types of cells,
including cancer cells, making them photosensitive [24].
ALA-induced endogenous PpIX accumulation thus consti-
tutes a photosentization process in which the selectivity of
neoplastic cells in synthesizing and/or accumulating PpIX
may be exploited to enhance the eﬃcacy of PDT and
photodynamic diagnosis.
PpIX has many other advantages. It is an essentially
monomeric compound with a high ﬂuorescence yield [25]
andphotosensitizingcapabilityduetoitsgoodsingletoxygen
quantum eﬃciency [26, 27] and is rapidly metabolized in
vivo [28]. Animal and human studies have shown that
ALA induces PpIX clearance from the skin within 24 hours
after systemic, topical, or intradermal administration [24],
whereas hematoporphyrin derivatives cause prolonged skin
photosensitivity (1 to 2 months).
Not all cell lines can synthesize PpIX in vitro after
ALA incubation in order to provide the reproducible in
vitro assays required for in vivo studies of ALA-induced
PDT. HepG2, a human hepatocarcinoma cell line, has
been enzymatically well characterized to synthesize PpIX
endogenously from exogenous ALA [29].
4.Photodynamic Diagnosisand
Fluorescence-Guided Microsurgery
In photodynamic diagnosis and ﬂuorescence-guided neu-
rosurgery [9, 10, 12, 15, 16], ALA is used for intraoper-
ative labeling of the border regions of malignant gliomas
inﬁltrated by alive clonogenic tumor cells and is helpful
in precise resection of those regions. ALA is converted
to PpIX in the body and emits red ﬂuorescence, with
the excitation of blue-violet light. As PpIX preferentially
accumulates in the tumor tissue in comparison with normal
tissue, this red ﬂuorescence becomes a good hallmark for
discrimination between normal and tumor tissues, especially
in malignant gliomas, which have inﬁltrative characteristics.
Approximately 80% to 90% of the malignant gliomas show
this red ﬂuorescence in surgery, while only a limited number
of metastatic brain tumor cases do not. In the surgery
for metastatic brain tumor and lesionectomy for radiation
necrosisandneurodegenerativedisease,whitematteraround
the lesion shows weak and vague ﬂuorescence, which also
provides us with a hallmark in the surgery. Additionally,
in meningioma, some tumors showed the red ﬂuorescence,
which is especially helpful in the removal of the inﬁltrative
portion in the bone and normal parenchyma [12]. Clinical
data indicate that ALA-photodynamic diagnosis-assisted
resection of malignant gliomas may result in statistically
signiﬁcant prolongation of postoperative survival [15, 16].
Ongoing research concentrates also on the use of ALA for a
selective elimination of glioma cells in situ and on lipophilic
ALA derivatives with more favorable pharmacokinetic prop-
erties.
There is a question still remaining unanswered, namely:
Why does PpIX accumulate in the tumor tissue more
preferentially than in normal tissue? In order to answer
for this question, we analyzed the expression levels of
major enzymes and transporters involved in biosynthesis
and metabolism of porphyrin. To determine mRNA levels
of those enzymes and transporters, we design quantitative
PCR primers (Table 1) and then compared their expression
proﬁles between glioma and normal tissues (Figure 2(a)).
The mRNA level of ABC transporter ABCG2 was found
to be signiﬁcantly lower in malignant glioma cells in the
brain tumor that exhibited strong ﬂuorescence of PpIX
after ALA treatment (Figure 2(b)), whereas the surrounding
normal cells emitted weak and vague ﬂuorescence. These
results suggest that ABCG2, a porphyrin eﬄux pump, is
downregulated in tumors and thereby PpIX is facilitated to
accumulate in cancer cells.Advances in Pharmacological Sciences 3
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Figure 1: Schematic illustration of the biosynthesis and catabolism of heme. Rectangles indicate the enzymes involved in heme metabolism.
Heme molecules are synthesized from glycine and succinyl Co-A via eight-stepped enzymatic reactions. ALA: γ-aminolevulinic acid;
PBG: porphobilinogen. Heme, thus formed, is catabolized to biliverdin by the microsomal enzyme heme oxygenase 1. Biliverdin is
subsequently metabolized to bilirubin by biliverdin reductase. ABC transporter ABCB6 is considered to be responsible for the import of
coproporphyrinogen III into mitochondria, whereas ABCG2 transports porphyrins across the plasma membrane to maintain intracellular
porphyrin homeostasis. ABCG2-mediated porphyrin transport can be inhibited by drugs, such as protein kinase inhibitors, as shown in
Figure 5.
5. Human ABC Transporter ABCG2 in
Cancer Chemotherapy and PDT
Human ABC transporter ABCG2, originally named Breast
Cancer Resistant Protein (BCRP), was ﬁrst discovered in
doxorubicin-resistant breast cancer cells [30]. Since the same
transporter has also been found in the human placenta
[31]a sw e l la si nd r u g - r e s i s t a n tc a n c e rc e l l ss e l e c t e di n
mitoxantrone [32], the transporter was also called ABCP or
MXR1. The ABCG2 gene is located on chromosome 4q22
and spans over 66kb, comprising 16 exons and 15 introns.
ABCG2 is classiﬁed in the G-subfamily of human ABC
transporter genes according to the designated international
nomenclature. Compared with the molecular structures of
thewell-knownmultidrugresistancetransportersABCB1(P-
gp/MDR1) and ABCC1 (MRP1), ABCG2 is a so-called “half
ABC transporter” bearing six transmembrane domains and
one ATP-binding cassette. Human ABCG2 has recently been
shown to exist in the plasma membrane as a homodimer
bound through disulﬁde-bonded cysteine residues [16, 33,
34]. Treatment with mercaptoethanol reduced the apparent
molecular weight of ABCG2 from 140,000 to 70,000. Based
on the cDNA sequence, a total of eleven cysteine residues
exist in the ABCG2 protein. Among them, three cysteine
residues in the extra-cellular loop of ABCG2 play pivotal
roles in homodimer formation or protein expression levels.
While Cys603 is involved in homodimer formation, Cys592
and Cys608 appear to be even more important for the
formation of an intramolecular disulﬁde bond that greatly
aﬀects the protein stability as well as plasma membrane
targeting of the ABCG2 protein [34, 35]. Recent studies have
demonstrated that the N-linked glycan bound to Asn5964 Advances in Pharmacological Sciences
Table 1: PCR primers to quantitatively measure the mRNA levels of PEPT1, PEPT2, ALAS1, ALAD, HMBS, UROS, UROD, ABCB6 CPOX,
PPOX, ABCG2, FECH, HO-1, and HIF1alpha.
Gene F/R Primer sequence Position Tm
PEPT1 Forward CCCTGAAGTGAAGGTGTTTGAAGATA 1772–1797 60.6
NM 005073 Reverse GAATTGGCCCCTGACATGAA 2168–2188 59.3
PEPT2 Forward CTACCACAATATGCCCTGGTTACA 1894–1917 58.8
NM 001145998 Reverse GCCACTGAACTGTGCCACAA 2045–2064 59.3
ALAS1 Forward GGATTCGAAACAGCCGAGTG 1371–1390 59.3
NM 000688 Reverse GAAGGTGATTGCTCCAAACTCAT 1542–1564 58.3
ALAD Forward CCTCGGTTCCAACCAACTGAT 157–177 59.8
NM 000031 Reverse GATAGGCTGTATGTCATCAGGAACA 319–343 58.2
HMBS Forward CAAGGACCAGGACATCTTGGAT 835–856 58.9
NM 000190 Reverse CCAGACTCCTCCAGTCAGGTACA 984–1006 59.2
UROS Forward TCAGCACTGCCTCTTCTATTTCC 668–691 58.7
NM 000375 Reverse CTGGGTGTGCAACTGTCTGATAC 761–789 58.3
UROD Forward CGGGAGTGTGTGGGGAA 982–998 57.2
NM 000374 Reverse AAGCAGACGTGAGTGTTTATGCA 1178–1200 58.6
ABCB6 Forward CAGAAGGGCCGTATTGAGTTTG 2033–2054 59.6
NM 005689 Reverse ATTGTCGGCGATGGTGTCA 2308–2326 59.5
CPOX Forward GGCGGAGATGTTGCCTAAGAC 401–421 59.7
NM 000097 Reverse AATGCTCACCCCAGCCTTTT 709–728 59.5
PPOX Forward CAGGAGTCCTGGGAATCGTGTA 1251–1272 59.9
NM 000309 Reverse TGCCTAGCTGACTCTAGTTTTTGC 1509–1533 58.1
FECH Forward GGAAATCCATTGTTCTCTAAGGC 1252–1274 57.0
NM 001012515 Reverse CTAAATAACACCCTCTCCACATCG 1462–1485 57.8
ABCG2 Forward CTAAGCAGGGACGAACAATCATC 1188–1210 58.8
NM 004827 Reverse TCCTGCTTGGAAGGCTCTATG 1447–1467 58.2
HIF-1alpha Forward GGCGCGAACGACAAGAA 420–436 58.0
NM 001530 Reverse CAAAACCATCCAAGGCTTTCA 682–702 58.7
HO-1 Forward GCTCAAAAAGATTGCCCAGAA 518–538 58.1
NM 002133 Reverse TCACATGGCATAAAGCCCTACA 926–947 59.1
PEPT1: oligopeptide transporter 1; PEPT2: oligopeptide transporter 2; ALAS1: delta-aminolevulinate synthase 1; ALAD, delta-aminolevulinate dehydratase;
HMBS: hydroxymethylbilane synthase; UROS: uroporphyrinogen III synthase; UROD: uroporphyrinogen decarboxylase; ABCB6: ABC transporter B6;
CPOX: coproporphyrinogen oxidase; PPOX: protoporphyrinogen oxidase; FECH: ferrochelatase; ABCG2: ABC transporter G2 (BCRP); HIF-1alpha: hypoxia
inducible factor-1 alpha subunit; HO-1: heme oxygenase-1. F/R: forward or reverse primers; Tm: melting temperature.
is important for stabilizing nascent ABCG2 proteins by
facilitating homodimers in the endoplasmic reticulum (ER)
[36, 37].
ABCG2 is endogenously expressed in placental tro-
phoblast cells, in the epithelium of the small intestine
and liver canalicular membrane, as well as in ducts and
lobules of the breast. In particular, the high levels of
ABCG2 expression in trophoblast cells suggest that the
pump is responsible either for transporting compounds into
the fetal blood supply or for removing toxic metabolites.
The apical localization in the epithelium of the small
intestine and colon indicates a possible role of ABCG2 in
regulating the uptake of p.o. administered drugs [38]. It
has recently been reported that geﬁtinib (iressa) enhanced
the oral availability of irinotecan in mice [39], suggestive
of the potential inhibition of mouse Abcg2 by geﬁtinib in
the small intestine. On the other hand, ABCG2-knockout
mice are extremely sensitive to the dietary chlorophyll-
breakdown product pheophorbide a, which suggests that
ABCG2 expressed in the small intestine plays a critical role in
reducing the risk for developing diet-dependent phototoxic-
ity and protoporphyria [40]. Importantly, ABCG2 has a high
aﬃnity to porphyrins, for example, hematoporphyrin and
pheophorbide a [41]. ABCG2 transported protoporphyrin,
hematoporphyrin,andpheophorbideainanATP-dependent
manner [41–43].
6. Nrf2-MediatedInduction of ABCG2 and
HO-1 by Photoactivation of Porphyrins
Recent evidence indicates that PDT can kill cancer cells
directly by the eﬃcient induction of apoptotic as well as
nonapoptotic cell death pathways [7]. The identiﬁcation ofAdvances in Pharmacological Sciences 5
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Figure 2: The mRNA levels of PEPT1, PEPT2, ALAS1, ALAD,
HMBS, UROS, UROD, ABCB6 CPOX, PPOX, ABCG2, FECH, HO-
1, and HIF1alpha in malignant glioma cells in the brain tumor
and in the surrounding normal cells. Total RNA was extracted
from strong ﬂuorescence-emitting areas (brain tumor) as well
as from the surrounding area (mostly normal tissue) without
porphyrin ﬂuorescence. The ﬁrst strand cDNA was prepared from
the extracted total RNA in a reverse transcriptase (RT) reaction.
(a) The mRNA levels of the genes involved in the heme synthesis
and metabolism reactions were detected by quantitative PCR and
normalized to the mRNA level of GAPDH. (b) The relative mRNA
levels of those genes in both areas were compared, where the
relative mRNA level in the strong ﬂuorescence-emitting area (brain
tumor) was divided by that in nonﬂuorescence area (mostly normal
tissue).
the molecular eﬀectors regulating the cross-talk between cell
death and cell protection pathways is an area of intense
interest in the study of photokilling in cancer cells.
ABCG2 and heme oxygenase-1 (HO-1) are induced in
HepG2 cells by photoactivation of porphyrins and display
diﬀerent induction patterns (Figures 3(a) and 3(b)). The
induction of HO-1 was rapid and transient, whereas that
of ABCG2 was relatively slow. Nevertheless, Nrf2-speciﬁc
siRNA treatments caused signiﬁcant impairments in the
induction of both ABCG2 and HO-1 after the photoactiva-
tion of porphyrins [44], suggesting that Nrf2 is a common
regulator for the transcriptional activation of ABCG2 and
HO-1 genes.
Nrf2 is a basic region-leucine zipper- (bZip-) type
transcriptionfactorandplaysacriticalroleintranscriptional
upregulation of many target genes, including those for
metabolizing enzymes and transporters essential for cellular
defense in response to oxidative and/or electrophilic stress
[45, 46]. Nrf2 targets the ARE containing the consensus
sequence of 5 -A/GTGACNNNGC) [45]. Keap1, on the
other hand, is known to be a negative regulator of Nrf2 by
retrieving it in the cytoplasm (Figure 3(c)). Oxidative stress
and/or electrophilic attack lead to the dissociation of Nrf2
from Keap1 and thereby activate Nrf2 for transcriptional
regulation of ARE-dependent genes. Indeed, many genes
encoding detoxifying and antioxidant enzymes were found
to be regulated by Nrf2 [46, 47].
We have recently reported the potential role of the
Nrf2/Keap1 mechanism in the induction of human ABC
transporters as well as HO-1 in HepG2 cells under oxidative
stress [44, 48]. The siRNA-mediated knockdown of Nrf2
or Keap1 revealed that the induction of ABCG2 and
HO-1 under oxidative stress involves an Nrf2-dependent
mechanism. However, the time course of ABCG2 induction
is diﬀerent from that of HO-1. While the Nrf2/Keap1
mechanism may be involved in the oxidative stress-mediated
ABCG2 induction, the induction mechanism may be indi-
rect. Thus, we consider an alternative mechanism of so-
called“trans-activation”fortheinductionoftheABCG2gene
[48].
The activation and nuclear translocation processes of
Nrf2 in HO-1 induction seem to be more complex than
previously expected. As shown in Figure 3(c), at least three
distinct pathways may be involved in the activation of the
Nrf2 protein leading to HO-1 induction: oxidation of critical
cysteinyl residues of the Keap1 protein and concomitant
inhibition of ubiquitination activity of Keap1 (Pathway i);
phosphorylationoftheNrf2proteinviaproteinkinases,such
as p38MAPK, PI3K, PKC, and PERK (Pathway ii); and direct
binding of heme to Bach1 and facilitation of Nrf2/small Maf
heterodimer formation (Pathway iii).
The HO-1 induction is dependent on transcription and
de novo protein synthesis, and it is preceded by the nuclear
accumulation of the Nrf2 transcription factor. In pathway
(i), Nrf2 is repressed under quiescent conditions, where
Keap1 and Cul3 constitute a unique ubiquitin E3 ligase
that leads to the degradation of Nrf2. Upon exposure to
oxidants/electrophiles, the enzymatic activity of this ligase
complex is inhibited and the complex fails to degrade
Nrf2, resulting in the transcriptional activation of Nrf2
target genes [47, 49]. Cys151 of Keap1 reportedly plays an
important role to facilitate Nrf2 activation in response to
oxidants/electrophiles [49].
Regarding pathway (ii), Martin et al. [50]r e p o r t e d
that HO-1 expression is regulated through the PI3K/Akt
pathway and the Nrf2 transcription factor in response to
the antioxidant phytochemical carnosol. Kocanova et al. [51]
more recently characterized the signaling pathways and the
mechanisms leading to the upregulation of HO-1 in cancer
cells subjected to hypericin-based PDT. They have shown
that HO-1 induction mechanisms involve the p38MAPK and
PI3K signaling cascade. Besides p38MAPK and PI3K, the6 Advances in Pharmacological Sciences
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Figure 3: (a) Time courses of changes in the mRNA levels of heme oxygenase-1 (HO-1), ABCG2, and ABCB6 in HepG2 cells incubated
with protoporphyrin IX (PpIX) and exposed to visible light. In dark conditions, HepG2 cells (1 × 106 cells) were ﬁrst incubated with 10μM
PpIX in Dulbecco’s modiﬁed Eagle’s medium at 37◦C under 5% CO2 gas for 4 hours. Thereafter, the incubation medium was replaced with
fresh incubation medium. Cells were then exposed to visible light for 90 min, where cell culture dishes containing HepG2 cells were placed
on a light viewer (Hakuba Model 5700) in an incubation chamber (37◦C, 5% CO2). Cells were subsequently incubated in the dark at 37◦C
under 5% CO2 gas for 22.5 hours. The whole incubation was performed for a total of 28 hours, as indicated in the ﬁgure. (b) As the control
experiments without light exposure, HepG2 cells (1 × 106 cells) were incubated with 10μM PpIX in the same way as described above. PCR
primers to quantitatively measure mRNA levels of HO-1, ABCG2, ABCB6, and GAPDH are described in [44]. (c) Schematic illustration
for the activation of Nrf2 via three diﬀerent pathways ((i), (ii), and (iii)). Pathway (i), under homeostatic conditions, Nrf2 is sequestered in
the cytoplasm by the Keap1-Cul3 complex and rapidly degraded in a ubiquitin-proteasome-dependent manner. After an oxidative challenge
(e.g., 1O2), oxidation of two reactive cysteine residues of Keap1 inhibits the ubiquitination reaction of Nrf2 mediated by the Keap1-Cul3
complex, which results in both cytoplasmic accumulation and nuclear translocation of Nrf2. Pathway (ii), activation of Nrf2 is mediated by
protein kinases (PKs), such as p38MAPK, PI3K, PERK, and PKC. Pathway (iii), under normal conditions, the chromatin structure of HO-1
is in a preactivation state, but transcription is repressed by Bach1. Heme binds to Bach1, inhibiting its DNA binding activity and inducing
its nuclear export. In the nuclei, the activated Nrf2 dimerizes with small Maf nuclear protein for eﬀective binding to the ARE consensus
sequence in the promoter region of the HO-1 gene.Advances in Pharmacological Sciences 7
activation of Nrf2 is mediated by other protein kinases, such
as PERK and PKC, being dependent on cell types [52–57].
In pathway (iii), heme regulates the dynamic exchange
of Bach1 and Nrf2 in the Maf transcription factor network.
Igarashi and his colleagues proposed this direct interaction
model [58–61]. The transcription repressor Bach1 is a sensor
and eﬀector of heme that regulates the expression of HO-
1 and globin genes [62–65]. Under normal conditions,
the chromatin structure of HO-1 is in a preactivation
state, but transcription is repressed by Bach1. Heme binds
to Bach1, inhibiting its DNA binding activity [66]a n d
inducing its nuclear export [67]. Furthermore, heme induces
ubiquitination and degradation of the transcription factor
Bach1 [68]. As a consequence, heme induces the switching of
Nrf2/small Maf hetero-dimers, resulting in HO-1 expression
[69].
7.ClinicalImplications ofNrf2-Mediated
Induction of HO-1
The induction of HO-1 after photoactivation of PpIX or
Pheo a is most probably mediated by pathway (i), whereby
1O2 generated from the photooxidative reaction could
oxidize the critical cysteine residues of Keap1 and thereby
increase the nuclear availability of the Nrf2 pool. HO-1
catalyzes the oxidation of heme to biologically active prod-
ucts: carbon monoxide (CO), biliverdin, and ferrous iron. It
participates in maintaining cellular homeostasis and plays an
important protective role in the tissues by reducing oxidative
injury, attenuating the inﬂammatory response, inhibiting
cell apoptosis, and regulating cell proliferation. Induction of
HO-1 by hemin prior to irradiation is cytoprotective [51].
A growing body of evidence indicates that HO-1 activation
plays a pivotal role in the progression of tumors. HO-1 is
very often upregulated in tumor tissues, and its expression
is further increased in response to therapies. Many studies
have convincingly shown that upregulation of HO-1 signif-
icantly improves survival of hepatoma, melanoma, thyroid
carcinoma, chronic myelogenous leukemia, gastric cancer,
and colon cancer cell lines [70]. Increased transcription
and translation of HO-1 was observed in Chinese hamster
ﬁbroblasts following photodynamic stress or photofrin II
incubation[71].Nowisetal.recentlydemonstratedthatHO-
1 protected tumor cells against PDT-mediated cytotoxicity
[72]. On the other hand, HO-1 inhibitors or targeted knock-
down of HO-1 expression made the cultured cell lines much
more sensitive to anticancer therapy. Accordingly, inhibition
ofHO-1canbesuggestedasapotentialtherapeuticapproach
sensitizing tumors to radiation, chemotherapy, or PDT [70].
8. Pharmacogenomics of ABCG2 and
PotentialImpacton PDT
Single nucleotide polymorphisms (SNPs) of the ABCG2
gene have been suggested to be a signiﬁcant factor aﬀecting
patients’ responses to medication and/or the risk of diseases
[73–77]. Sequencing of the ABCG2 gene from human
samples has revealed over 80 diﬀerent, naturally occurring
sequence variations [75–77]. Among them, a total of 17
nonsynonymous polymorphisms have been reported for the
ABCG2 gene [41, 74, 78]( Figure 4(a)).
The most extensively studied among those SNPs with
potential clinical relevance is 421 C > A resulting in a
glutamine to lysine substitution (Q141K) in the ABCG2
protein. The Q141K SNP has been identiﬁed with varying
frequencies in diﬀerent ethnic groups and was found to
be the most relevant in Japanese and Chinese populations
(approximately 30% in the allele frequency). Low allele
frequencies (0% to 35%) are found in the Africans North
of the Sahara, sub-Saharan Africans, and African-American
subjects [74].
Q141K has been associated with lower levels of protein
expression and impaired transport in vitro [79–84]. The
polymorphismhasbeenstudiedinvivo;patientscarryingthe
SNP were found to have elevated plasma levels of geﬁtinib,
diﬂomotecan, and increased bioavailability of oral topotecan
[85–87]. Furthermore, the Q141K SNP was reportedly
associated with a higher incidence of diarrhea in nonsmall
cell lung cancer patients treated with geﬁtinib [88]. It has
been demonstrated that the reduced expression levels of
the Q141K variant may be due to its ubiquitin-mediated
proteasomal degradation [89].
The apparent Km value of ABCG2 WT toward hemato-
porphyrin was estimated to be 17.8μM[ 41]. To clarify the
possible physiological or pathological relevance of ABCG2
polymorphisms, we have functionally validated polymor-
phisms of ABCG2 [19, 41, 42, 78]. Based on the currently
available data on SNPs and acquired mutations, we have
created a total of 18 variant forms of ABCG2 (V12M,
G51C, Q126stop, Q141K, T153M, Q166E, I206L, F208S,
S248P, E334stop, F431L, S441N, R482G, R482T, F489L,
F571I, N590Y, and D620N) by site-directed mutagenesis
and expressed them in insect cells [41, 90]. The variants
Q126stop, F208S, S248P, E334stop, and S441N are defec-
tive in the transport of hematoporphyrin (Figure 4(b)).
The F489L variant showed impaired transport activity
(Figure 4(b)). Flp-In-293 cells expressing the F208S, S248P,
S441N, and F489L variants were sensitive to light when
cells were treated with pheophorbide a. Thus, it is likely
that humans with these alleles may be more susceptible to
porphyrin-induced phototoxicity.
9. Interaction of ABCG2 with Protein
KinaseandCDKInhibitors
Proteinkinasesarepotentialdrugtargetsforthetreatmentof
avarietyofdiseases,includingcancer[91].Inparticular,spe-
ciﬁc tyrosine kinase inhibitors are rapidly being developed as
new drugs for the inhibition of malignant cell growth and
metastasis. Most of these newly developed tyrosine kinase
inhibitorsarehydrophobicandthusrapidlypenetratethecell
membrane to reach intracellular targets.
T h eh u m a ng e n o m ee n c o d e sm o r et h a n5 0 0p r o t e i n
kinases, and this protein kinase family has been the subject
of intensive research for the development of novel anticancer
drugs [92]. Geﬁtinib and imatinib are new anticancer drugs8 Advances in Pharmacological Sciences
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Figure 4: (a) Schematic illustration of human ABCG2 and its nonsynonymous polymorphisms. SNP data on the polymorphisms of ABCG2
were obtained from the NCBI dbSNP database and recent publications. The variants R482G and R482T are acquired mutations. (b) ATP-
dependent transport of hematoporphyrin by ABCG2 and its variants. Plasma membrane vesicles expressing ABCG2 variants (50μgo f
protein) were incubated with 20μM hematoporphyrin in the presence or absence of 1mM ATP in the standard incubation medium at
37◦C for 10 minutes. The ATP-dependent transport of hematoporphyrin is normalized for the amount of ABCG2 protein. Data are from
[41].
that have been developed as inhibitors for EGFR tyrosine
kinase and BCR/ABL kinase, respectively. Recently, another
class family of protein kinases has been attracting particular
attention, namely, the cyclin-dependent kinases (CDKs),
which regulate critical processes of cell cycle progression and
gene transcription essential for cancer cell survival [93]. In
cancer, CDKs are deregulated in diﬀerent ways, such as by
the overexpression of cyclin E [94] and loss of p16INK4A,
a CDK inhibitor [95]. Thus, small-molecule chemicals that
speciﬁcally regulate or inhibit CDKs are of great interest in
drug discovery and development for cancer chemotherapy.
The QSAR analysis revealed that a structure having
one amine bonded to one carbon of a heterocyclic ring is
an important component for interaction with the ABCG2
protein [96]. In addition, fused heterocyclic ring(s) and two
substituents on a carbocyclic ring of the fused heterocyclic
ring(s) are also important chemical moieties for the inter-
action with ABCG2 [96]. Interestingly, many protein kinase
inhibitors carry such structural components within their
molecules. Based on the QSAR analysis, we hypothesized
that those CDK inhibitors would interact with the ABCG2
protein [37].Advances in Pharmacological Sciences 9
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Figure 5: (a) Chemical structures of CDK inhibitors: purvalanol A, WHI-P180, geﬁtinib, bohemine, roscovitine, and olomoucine. (b)
Inhibition of ABCG2-mediated hematoporphyrin transport by purvalanol A, WHI-P180, roscovitine, bohemine, or olomoucine. ABCG2-
expressing plasma membrane vesicles (20μg of protein) were incubated with 20μM hematoporphyrin in the presence of purvalanol A,
WHI-P180, roscovitine, bohemine, or olomoucine (ﬁnal concentration: 0, 0.3, 1, 3, 10, or 30μM) in the standard incubation medium
(0.25M sucrose and 10mM Tris/HEPES, pH 7.4, 1mM ATP, 10mM creatine phosphate, 100μg/mL of creatine kinase, 10 mM MgCl2)
at 37◦C for 10 min. Hematoporphyrin transported into membrane vesicles was detected [43]. Data are expressed as mean values ± SD
(n = 5).10 Advances in Pharmacological Sciences
10. PhotosensitivityEvokedby Inhibition of
ABCG2-MediatedPorphyrinTransport
Clinical photosensitizers, such as protoporphyrin, 2-(1-
hexyloxethyl)-2-devinyl pyropheophorbide a (photochlor),
and benzoporphyrin derivative monoacid ring A
(Verteporﬁn), were transported out of cells by ABCG2,
whereas this eﬀect was abrogated by the coadministration
of imatinib mesylate [97]. By increasing intracellular
photosensitizer levels in ABCG2-positive tumors, imatinib
mesylate or other ABCG2 transport inhibitors may enhance
the eﬃcacy and selectivity of clinical PDT [98]. In this
regard, we have reported that cellular phototoxicity was
evoked through the inhibition of human ABC transporter
ABCG2 by imatinib [42] and cyclin-dependent kinase
(CDK) inhibitors [43].
To gain further insights into drug-ABCG2 interac-
tions, the three-dimensional (3D) structures of those CDK
inhibitors (Figure 5(a)) were generated by ab initio MO
calculation [43]. Purvalanol A and WHI-P180 have a planar
structure, whereas bohemine, roscovitine, and olomoucine
do not. In the latter CDK inhibitors, the aromatic ring
is orthogonal to the purine ring [43]. Among the CDK
inhibitors tested (i.e., purvalanol A, WHI-P180, bohemine,
roscovitine, and olomoucine), purvalanol A was found to
be the most potent inhibitor for ABCG2-mediated hemato-
porphyrin transport (Figure 5(b)). Accordingly, it evoked
the photosensitivity of ABCG2-expressing Flp-In-293 cells
treated with pheophorbide a [43]. Thus, it is suggested that
the planar structure is an important factor for interactions
with the active site of ABCG2. Taken together, ABCG2 is one
of the critical factors that aﬀect the eﬃcacy of PDT as well as
chemotherapy of human cancer.
11. Concluding Remarks
ABCG2 was discovered a decade ago and has been stud-
ied in laboratories around the world, yielding a wealth
of knowledge akin to that gathered for ABCB1 (P-
glycoprotein/MDR1) and ABCC1 (MRP1). Chemotherapy
and PDT are eﬀective treatment options for human cancer.
However, individual diﬀerences among patients were also
noticed in their responses to those therapies. Gupta et
al. demonstrated interesting data that ABCG2 mRNA was
present in normal colorectal tissue but showed a 6-fold
decrease in colorectal cancer [98]. The downregulation of
ABCG2 mRNA and protein was also evident in cervical
cancer. Indeed, we have also found that ABCG2 expression
was downregulated in malignant glioma of human brain
tumor (Figure 2). These observations indicate that cancer-
associated downregulation of ABCG2 is likely to be a
common phenomenon in several tumors and that the
accumulationofclinicalphotosensitizersincanceroustissues
may be due, in part, to the reduced expression levels of
ABCG2 in cancer cells. On the other hand, induction of
ABCG2 and HO-1 is considered as critical factors for PDT,
and they can be readily induced by photo-oxidative stress
to protect cancer cells. Thus, investigations of molecular
mechanisms underlying the induction of those genes would
be of importance to create new strategies for individualized
PDT.
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